RRC ID 71735
Author Hermans D, Houben E, Baeten P, Slaets H, Janssens K, Hoeks C, Hosseinkhani B, Duran G, Bormans S, Gowing E, Hoornaert C, Beckers L, Fung WK, Schroten H, Ishikawa H, Fraussen J, Thoelen R, de Vries HE, Kooij G, Zandee S, Prat A, Hellings N, Broux B.
Title Oncostatin M triggers brain inflammation by compromising blood-brain barrier integrity.
Journal Acta Neuropathol
Abstract Oncostatin M (OSM) is an IL-6 family member which exerts neuroprotective and remyelination-promoting effects after damage to the central nervous system (CNS). However, the role of OSM in neuro-inflammation is poorly understood. Here, we investigated OSM's role in pathological events important for the neuro-inflammatory disorder multiple sclerosis (MS). We show that OSM receptor (OSMRβ) expression is increased on circulating lymphocytes of MS patients, indicating their elevated responsiveness to OSM signalling. In addition, OSM production by activated myeloid cells and astrocytes is increased in MS brain lesions. In experimental autoimmune encephalomyelitis (EAE), a preclinical model of MS, OSMRβ-deficient mice exhibit milder clinical symptoms, accompanied by diminished T helper 17 (Th17) cell infiltration into the CNS and reduced BBB leakage. In vitro, OSM reduces BBB integrity by downregulating the junctional molecules claudin-5 and VE-cadherin, while promoting secretion of the Th17-attracting chemokine CCL20 by inflamed BBB-endothelial cells and reactive astrocytes. Using flow cytometric fluorescence resonance energy transfer (FRET) quantification, we found that OSM-induced endothelial CCL20 promotes activation of lymphocyte function-associated antigen 1 (LFA-1) on Th17 cells. Moreover, CCL20 enhances Th17 cell adhesion to OSM-treated inflamed endothelial cells, which is at least in part ICAM-1 mediated. Together, these data identify an OSM-CCL20 axis, in which OSM contributes significantly to BBB impairment during neuro-inflammation by inducing permeability while recruiting Th17 cells via enhanced endothelial CCL20 secretion and integrin activation. Therefore, care should be taken when considering OSM as a therapeutic agent for treatment of neuro-inflammatory diseases such as MS.
Volume 144(2)
Pages 259-281
Published 2022-8-1
DOI 10.1007/s00401-022-02445-0
PII 10.1007/s00401-022-02445-0
PMID 35666306
MeSH Animals Blood-Brain Barrier* / metabolism Blood-Brain Barrier* / pathology Encephalomyelitis, Autoimmune, Experimental* / genetics Encephalomyelitis, Autoimmune, Experimental* / metabolism Encephalomyelitis, Autoimmune, Experimental* / pathology Endothelial Cells / metabolism Endothelial Cells / pathology Mice Mice, Inbred C57BL Multiple Sclerosis / metabolism Multiple Sclerosis / pathology Oncostatin M* / metabolism Oncostatin M* / pharmacology Oncostatin M Receptor beta Subunit / biosynthesis Oncostatin M Receptor beta Subunit / genetics Th17 Cells / metabolism Th17 Cells / pathology
IF 14.256
Mice RBRC02711